Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 5Recruiting 5Completed 3Unknown 2Withdrawn 1Suspended 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 5Carcinoma, Renal Cell 4Squamous Cell Carcinoma of Head and Neck 3Neoplasms 2Lung Neoplasms 2Urogenital Neoplasms 1Solid Tumor, Adult 1Recurrence 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Mesothelioma, Malignant 1Meningeal Neoplasms 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 85pembrolizumab 78Pemetrexed 68Cisplatin 56Paclitaxel 45osimertinib 41Nivolumab 40durvalumab 37Docetaxel 33atezolizumab 20Gemcitabine 18Radiotherapy 17Radiosurgery 16amivantamab 15Ipilimumab 15130-nm albumin-bound paclitaxel 14Taxes 13Specimen Handling 12Magnetic Resonance Spectroscopy 12Crizotinib 11lazertinib 9Radiation 9Immunoglobulin G 9Drug Therapy 9Disulfides 9Bevacizumab 9tislelizumab 8cemiplimab 8alectinib 8Erlotinib Hydrochloride 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinoma, Non-Small-Cell Lung × Interleukin-2 × Clear all
NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

University of California, Davis

Phase 1/2 Active not recruiting
18 enrolled 13 charts
DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡